Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd (KMDA) is a global biopharmaceutical company focused on specialty plasma-derived therapies and other biopharmaceutical products for rare and serious conditions. Its news flow reflects activity across commercial operations, clinical programs, plasma collection, and corporate strategy.
On this page, readers can follow Kamada news related to its proprietary products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and equine-based anti-snake venom products. Company announcements frequently discuss revenue trends, adjusted EBITDA, and guidance, highlighting the contribution of its Proprietary Products and Distribution segments, including biosimilar launches in Israel and supply agreements in markets such as Canada.
News items also cover clinical and post-marketing research, including updates on the InnovAATe Phase 3 trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency and its subsequent discontinuation following an interim futility analysis, as well as the SHIELD study evaluating CYTOGAM in high-risk kidney transplant recipients. Regulatory and operational milestones, such as FDA approval of the Houston, Texas plasma collection center and expansion of plasma collection capacity across Kamada’s three Texas sites, are recurring topics.
Investors and followers of KMDA stock can use this feed to track quarterly and annual financial results, guidance updates, tender awards like the Canadian Blood Services supply extension, and participation in healthcare and investor conferences. Regularly reviewing this page provides a consolidated view of Kamada’s commercial progress, R&D developments, and strategic initiatives as reported in its press releases and related filings.
Kamada (NASDAQ: KMDA), a commercial stage biopharmaceutical company specializing in rare and serious conditions through plasma-derived products, has scheduled its Q2 and H1 2025 financial results announcement for August 13, 2025, before U.S. markets open.
The company will host an investment community conference call at 8:30 AM ET on the same day, where management will discuss results and take questions. Investors can join via phone or webcast, with specific dial-in numbers provided for U.S., Israeli, and international participants.
- Opening a new plasma collection center in San Antonio, TX, expected to generate $8-10 million in annual revenues
- Launch of CYTOGAM® post-marketing research program
- Secured a $25 million contract for KAMRAB and VARIZIG supply in Latin America (2025-2027)
- Continued progress in Phase 3 InnovAATe clinical trial for inhaled AAT therapy
Kamada Ltd. (NASDAQ: KMDA), a commercial stage biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, has scheduled its Q1 2025 financial results announcement for May 14, 2025, before U.S. markets open.
The company will host a conference call for the investment community at 8:30am ET on the same day. Participants can join via phone using specific dial-in numbers for U.S., Israeli, and International callers, or watch the webcast live online.
Kamada (NASDAQ: KMDA) has provided an update on tax withholding procedures for its previously announced special cash dividend of $0.20 per share (total ~$11.5 million). The dividend will be paid on April 7, 2025, to shareholders of record as of March 17, 2025.
The company has obtained a tax ruling from the Israel Tax Authority that allows Nasdaq shareholders who are residents of countries with Israeli tax treaties to potentially qualify for reduced withholding tax rates. The standard Israeli withholding tax rates are 30% for substantial shareholders and 25% for others.
To benefit from reduced rates, eligible shareholders must submit required documentation to IBI Trust Management (the appointed Tax Agent) by May 5, 2025. The company will initially withhold 25% of the dividend amount, with potential refunds available to qualifying shareholders who complete the necessary paperwork.
Kamada (NASDAQ: KMDA) announced the opening of a new plasma collection center in San Antonio, Texas, marking its third such facility. The 11,100 square foot center, operated by Kamada Plasma, will feature nearly 50 donor beds with an estimated annual collection capacity of 50,000 liters.
The facility will collect both normal source plasma and specialty plasma (Anti-Rabies and Anti-D), supporting the company's increasing demand for hyper-immune plasma while aiming to reduce raw material costs. At full capacity, the center is projected to generate $8-10 million in annual revenue from normal source plasma sales to third parties.
Kamada plans to submit approval applications to the U.S. FDA and European Medicines Agency in the second half of 2025, with anticipated approval decisions expected within 9-12 months of submission.
Kamada (NASDAQ: KMDA) reported strong financial results for 2024, achieving record revenues of $161.0 million, a 13% increase from 2023. The company's adjusted EBITDA reached $34.1 million, up 42% year-over-year, with a 21% margin.
Key financial highlights include net income of $14.5 million ($0.25 per diluted share), up 75% year-over-year, and operating cash flow of $47.6 million. The company ended 2024 with a cash balance of $78.4 million.
Looking ahead, Kamada affirmed its 2025 guidance, projecting revenues of $178-182 million and adjusted EBITDA of $38-42 million. The company also declared a special cash dividend of $0.20 per share, totaling approximately $11.5 million.
Growth drivers include expansion of plasma collection operations, with a third U.S. center opening soon, and advancement of the Inhaled AAT Phase 3 trial, which received FDA approval for reduced patient enrollment to 180 subjects.
Kamada (NASDAQ: KMDA) has declared its first-ever special cash dividend of $0.20 per share (approximately NIS0.72), totaling around $11.5 million. The dividend will be paid on April 7, 2025, to shareholders of record as of March 17, 2025.
The announcement follows Kamada's record revenue and profitability performance in 2024. CEO Amir London emphasized the company's strong financial position and outlined four growth pillars: organic commercial growth, business development and M&A transactions, expansion of plasma collection operations, and advancement of their lead product candidate, Inhaled AAT.
The company will withhold tax on the dividend according to Israeli tax law and is awaiting a ruling from the Israel Tax Authority regarding tax withholding for non-Israeli shareholders.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company specializing in rare and serious conditions and specialty plasma-derived products, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results announcement for March 5, 2025, before U.S. markets open.
The company will host an investment community conference call at 8:00 AM ET on the same day. Investors can participate through various dial-in numbers: 1-877-413-7208 (U.S.), 1-201-689-8555 (International), or 1-809-406-247 (Israel) using conference ID 13751522. The call will also be available via webcast.